Innoviva, Inc. (INVA) stock analysis
INVA · Innoviva, Inc.
Latest recorded price: USD 18.49
Model-estimated fair value: USD 75.12. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Biotechnology
At $18.49, INVA trades 75.4% below the model's base-case value of $75.12. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $59.27 in the conservative case and $93.40 in the optimistic case, with a valuation confidence score of 55/100. About 72% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 7.5%, free cash flow margin 47.6%, ROIC 15.2%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- Ionis Pharmaceuticals, Inc. (IONS)
- Iovance Biotherapeutics, Inc. (IOVA)
- Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
- Korsana Biosciences, Inc. (KRSA)
- Krystal Biotech, Inc. - Common Stock (KRYS)
- Kymera Therapeutics, Inc. - Common Stock (KYMR)
- Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
- Madrigal Pharmaceuticals, Inc. - Common Stock (MDGL)